CIM
VRTX icon

Contravisory Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Contravisory Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,644
Closed -$662K – 459
2024
Q4 		$662K Sell
1,644
-15
-0.9% -$6.95K 0.14% 97
2024
Q3 		$772K Buy
1,659
+192
+13% +$92.2K 0.17% 86
2024
Q2 		$688K Sell
1,467
-62
-4% -$26.9K 0.15% 86
2024
Q1 		$639K Sell
1,529
-30
-2% -$12.7K 0.14% 92
2023
Q4 		$634K Buy
1,559
+365
+31% +$135K 0.16% 85
2023
Q3 		$415K Sell
1,194
-42
-3% -$14.7K 0.12% 118
2023
Q2 		$435K Buy
+1,236
New +$416K 0.12% 127
2018
Q1 		– Sell
-30
Closed -$4K – 455
2017
Q4 		$4K Sell
30
-6
-17% -$888 ﹤0.01% 306
2017
Q3 		$5K Buy
+36
New +$5.42K ﹤0.01% 296
2016
Q1 		– Sell
-65
Closed -$8K – 235
2015
Q4 		$8K Hold
65
– – ﹤0.01% 131
2015
Q3 		$7K Hold
65
– – ﹤0.01% 142
2015
Q2 		$8K Hold
65
– – ﹤0.01% 157
2015
Q1 		$8K Hold
65
– – ﹤0.01% 132
2014
Q4 		$8K Hold
65
– – ﹤0.01% 134
2014
Q3 		$7K Sell
65
-45
-41% -$4.28K ﹤0.01% 125
2014
Q2 		$10K Hold
110
– – ﹤0.01% 114
2014
Q1 		$8K Hold
110
– – ﹤0.01% 132
2013
Q4 		$8K Hold
110
– – ﹤0.01% 107
2013
Q3 		$8K Hold
110
– – ﹤0.01% 100
2013
Q2 		$9K Buy
+110
New +$8.1K ﹤0.01% 108

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Contravisory Investment Management's VRTX Position: Q1 2025 in Review

Contravisory Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,644 shares — an estimated $662K sold.

Contravisory Investment Management first reported a position in VRTX in Q2 2013 and held it in 20 quarters. The position peaked at $772K in Q3 2024. 1,617 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Contravisory Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 1,644 Vertex Pharmaceuticals shares in Q1 2025, an estimated $662K.
  • Contravisory Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Contravisory Investment Management's Vertex Pharmaceuticals position peaked at $772K in Q3 2024.
  • 1,617 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Contravisory Investment Management's 13F filing for Q1 2025, filed 10 Apr 2025.